Edition:
United States

Galena Biopharma Inc (GALE.OQ)

GALE.OQ on NASDAQ Stock Exchange Capital Market

0.32USD
14 Dec 2017
Change (% chg)

$0.04 (+14.24%)
Prev Close
$0.28
Open
$0.28
Day's High
$0.32
Day's Low
$0.28
Volume
179,258
Avg. Vol
102,544
52-wk High
$3.60
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

Galena Biopharma posts Q3 loss $0.15/shr from continuing operations
Thursday, 9 Nov 2017 04:30pm EST 

Nov 9 (Reuters) - Galena Biopharma Inc :Galena Biopharma reports third quarter 2017 financial results.Q3 loss per share $0.15 from continuing operations.Galena Biopharma Inc - ‍cash and cash equivalents of approximately $12.9 million as of September 30, 2017, compared with $18.1 million as of December 31, 2016​.  Full Article

Galena Biopharma says co and Cardinal Health entered into a settlement relating to product swap agreement​
Wednesday, 18 Oct 2017 05:44pm EDT 

Oct 19 (Reuters) - Galena Biopharma Inc :Galena Biopharma Inc says on October 12, co and Cardinal Health entered into a settlement relating to product swap agreement​ - SEC filing.Galena Biopharma Inc - ‍pursuant to agreement , co, Cardinal agreed to resolve all of their outstanding disputes over a product swap agreement​.Galena Biopharma Inc - ‍Cardinal will destroy all of zuplenz oral soluble film that is returned as a result of product swap agreement.Galena Biopharma Inc - ‍product swap agreement with Cardinal will be terminated as of effective date of agreement​.  Full Article

Galena Biopharma announces completion of enrollment in two NeuVax™ clinical trials in combination with Trastuzumab
Thursday, 28 Sep 2017 07:05am EDT 

Sept 28 (Reuters) - Galena Biopharma Inc :Galena Biopharma Inc announces completion of enrollment in two NeuVax™ (nelipepimut-s) clinical trials in combination with Trastuzumab.Galena Biopharma Inc - ‍look forward to interim results next year for phase 2b trial and primary endpoints for both trials in 2019​.Galena Biopharma Inc - ‍recommendation from dsmb was to continue her2 3+ trial unmodified.​.  Full Article

Galena Biopharma, unit of co and Biovascular, enters amendment of exclusive license agreement
Monday, 11 Sep 2017 07:32am EDT 

Sept 11 (Reuters) - Galena Biopharma Inc ::Galena Biopharma-‍on Sept 5, unit of co and Biovascular, entered amendment of exclusive license agreement between MPI and BVI dated December 20, 2013.Galena Biopharma - ‍pursuant to amendment parties agreed to resolve outstanding disputes over license agreement, to modify certain terms of agreement​.Galena Biopharma- ‍amendment to eliminate 3pct royalty rate on annual net sales of $50 million, 4pct royalty now applies to annual net sales of up to $100 million​.  Full Article

Galena Biopharma and Biovascular Inc reaffirm GALE-401 partnership
Monday, 11 Sep 2017 07:05am EDT 

Sept 11 (Reuters) - Galena Biopharma Inc ::Galena Biopharma and Biovascular Inc reaffirm GALE-401 partnership.Galena Biopharma-‍working in conjunction with Sellas Life Sciences, co's proposed merger candidate, Biovascular has withdrawn its notice of termination​.Galena - Co, Biovascular amended license agreement to advance asset either through internal clinical development or by seeking licensing partner​.Galena Biopharma Inc - co ‍has completed majority of work for initiation of a phase 3 trial in patients with essential thrombocythemia​.  Full Article

U.S. DOJ says Galena Biopharma to pay over $7.55 mln to resolve alleged claims
Friday, 8 Sep 2017 03:17pm EDT 

Sept 8 (Reuters) - Department of Justice: :Department of Justice says "Galena Biopharma Inc to pay more than $7.55 million to resolve alleged false claims related to opioid drug".Settlement resolves lawsuit filed by relator Lynne Dougherty; as part of Sept. 8 resolution, Dougherty will receive over $1.2 million‍​.  Full Article

Galena Biopharma reports Q2 loss per share $0.22
Monday, 14 Aug 2017 04:30pm EDT 

Aug 14 (Reuters) - Galena Biopharma Inc -:Galena Biopharma reports second quarter 2017 financial results.Q2 loss per share $0.19 from continuing operations.Q2 loss per share $0.22.  Full Article

Galena Biopharma files for non-timely 10-Q- SEC Filing‍​
Wednesday, 9 Aug 2017 05:12pm EDT 

Aug 9 (Reuters) - Galena Biopharma Inc :Files for non-timely 10-Q‍​.Galena Biopharma - cannot complete by Aug 9, additional changes to June 30, 2017 form 10-q to include all necessary disclosure resulting from merger.Galena Biopharma says anticipates it will file the June 30, 2017 form 10-Q within the "grace" period provided by securities exchange act rule 12b-25.  Full Article

Galena Biopharma enters into merger agreement with Sellas Life Sciences Group
Tuesday, 8 Aug 2017 06:00am EDT 

Aug 8 (Reuters) - Galena Biopharma Inc :Galena Biopharma enters into merger agreement with Sellas Life Sciences Group.Galena Biopharma Inc - under terms of merger agreement, existing sellas shareholders will receive newly issued shares of Galena common stock.Galena Biopharma Inc - ‍under terms of merger agreement, existing Sellas shareholders will receive newly issued shares of Galena common stock​.Galena Biopharma Inc - on a pro forma basis, assuming completion of proposed merger, Galena stock and warrant holders are expected to own about 32.5%.Galena Biopharma Inc - on pro forma basis, assuming completion of proposed merger, Sellas shareholders will own approximately 67.5% of combined co.Galena Biopharma - Galena stock and warrant holders are expected to own about 32.5%, and sellas shareholders will own approximately 67.5% of combined company.Galena Biopharma- ‍entered an all stock definitive merger agreement under which Sellas will merge into and become an indirect, wholly-owned unit of co​.Galena Biopharma Inc - transaction has also been unanimously approved by sellas board of directors.Galena Biopharma Inc - a majority of Sellas shareholders have agreed to vote in favor of transaction.Galena Biopharma Inc - upon closing of transaction, name of combined company will become Sellas Life Sciences Group Inc.Galena Biopharma - upon closing of transaction shares of combined are expected to continue trading on Nasdaq capital market under new ticker symbol SLS.  Full Article

Galena Biopharma updates on exploring strategic options
Wednesday, 12 Jul 2017 06:30am EDT 

July 12 (Reuters) - Galena Biopharma Inc -:Galena Biopharma provides corporate update.Galena Biopharma-‍with support of Canaccord Genuity, had interactions with cos to explore options for monetizing some/all clinical development programs​.Galena Biopharma - has had extensive interactions with numerous cos to explore options for monetizing some,all of its clinical development programs​.Galena Biopharma-‍exploring options for monetizing some/all of clinical development programs through license or sale of assets, and/or sale, merger among others.Galena Biopharma Inc - ‍management has significantly reduced staffing levels and certain operational expenses to preserve cash​.Galena Biopharma Inc - ‍work remains ongoing to advance its two core clinical programs, gale-401 and neuvax​.Galena Biopharma Inc says has ‍had initial interest in potential transactions from a number of companies​.  Full Article

BRIEF-Galena Will Adjourn Special Meeting Until Friday, Dec 29

* GALENA WILL ADJOURN SPECIAL MEETING UNTIL FRIDAY, DECEMBER 29, 2017, URGES STOCKHOLDERS TO VOTE